ADUHELM (aducanumab-avwa)
ALZHEIMER'S DISEASE AGENTS - AMYLOID DIRECTED MC ANTIBODY · MILD TO MODERATE ALZHEIMER'S TYPE DEMENTIA
BIOGEN-IDEC
Drug class
Alzheimer's Disease Agents - Amyloid Directed MC Antibody
Alzheimer's Disease Agents - Amyloid Directed MC Antibody is a formulary and compendia classification representing monoclonal antibodies engineered to target and clear aggregated beta-amyloid from the brain. Read more about Alzheimer's Disease Agents - Amyloid Directed MC Antibody
4 drugs in this class 3 manufacturers
Drugs in Alzheimer's Disease Agents - Amyloid Directed MC Antibody
LEQEMBI (lecanemab-irmb)
ALZHEIMER'S DISEASE AGENTS - AMYLOID DIRECTED MC ANTIBODY · ALZHEIMER'S DISEASE
EISAI INC.
KISUNLA (donanemab-azbt)
ALZHEIMER'S DISEASE AGENTS - AMYLOID DIRECTED MC ANTIBODY · ALZHEIMER'S DISEASE
Eli Lilly and Company
LEQEMBI IQLIK (lecanemab-irmb)
ALZHEIMER'S DISEASE AGENTS - AMYLOID DIRECTED MC ANTIBODY · ALZHEIMER'S DISEASE
EISAI INC.
Filter & compare in the drug finder →
Opens the drug finder with Alzheimer's Disease Agents - Amyloid Directed MC Antibody preselected. Add indication or manufacturer filters there.
Alzheimer's Disease Agents - Amyloid Directed MC Antibody is a formulary and compendia classification representing monoclonal antibodies engineered to target and clear aggregated beta-amyloid from the brain.
By binding to specific conformations of amyloid-beta—such as soluble protofibrils or insoluble plaques—these disease-modifying agents facilitate microglial-mediated clearance to slow pathophysiological neurodegeneration and cognitive decline.
Clinically, these agents are indicated for adult patients with early symptomatic Alzheimer's disease, specifically those diagnosed with mild cognitive impairment or mild dementia with confirmed brain amyloid pathology.
-
alz.org
Alzheimer's Disease Agents - Amyloid Directed MC Antibody is a formulary and compendia classification representing monoclonal antibodies engineered to target and clear aggregated beta-amyloid from the brain
-
nih.gov
Alzheimer's Disease Agents - Amyloid Directed MC Antibody is a formulary and compendia classification representing monoclonal antibodies engineered to target and clear aggregated beta-amyloid from the brain
-
fda.gov
By binding to specific conformations of amyloid-beta—such as soluble protofibrils or insoluble plaques—these disease-modifying agents facilitate microglial-mediated clearance to slow pathophysiological neurodegeneration and cognitive decline
-
neurology.org
By binding to specific conformations of amyloid-beta—such as soluble protofibrils or insoluble plaques—these disease-modifying agents facilitate microglial-mediated clearance to slow pathophysiological neurodegeneration and cognitive decline
-
practicalneurology.com
By binding to specific conformations of amyloid-beta—such as soluble protofibrils or insoluble plaques—these disease-modifying agents facilitate microglial-mediated clearance to slow pathophysiological neurodegeneration and cognitive decline
-
cms.gov
Clinically, these agents are indicated for adult patients with early symptomatic Alzheimer's disease, specifically those diagnosed with mild cognitive impairment or mild dementia with confirmed brain amyloid pathology
-
fda.gov
Clinically, these agents are indicated for adult patients with early symptomatic Alzheimer's disease, specifically those diagnosed with mild cognitive impairment or mild dementia with confirmed brain amyloid pathology
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.